NCT05185869View on ClinicalTrials.gov

SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions
Pancreatic Cancer
Interventions
DRUG

SHR6390

SHR6390, Oral Administration

DRUG

Nab-paclitaxel

Paclitaxel-albumin, Intravenous Injection

DRUG

Gemcitabine

Gemcitabine, Intravenous Injection

Trial Locations (1)

200025

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER